JP2017516868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516868A5 JP2017516868A5 JP2017516256A JP2017516256A JP2017516868A5 JP 2017516868 A5 JP2017516868 A5 JP 2017516868A5 JP 2017516256 A JP2017516256 A JP 2017516256A JP 2017516256 A JP2017516256 A JP 2017516256A JP 2017516868 A5 JP2017516868 A5 JP 2017516868A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- patient
- thip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 60
- 230000004770 neurodegeneration Effects 0.000 claims description 23
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 206010012289 Dementia Diseases 0.000 claims description 11
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- ZDZDSZQYRBZPNN-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrochloride Chemical compound Cl.C1NCCC2=C1ONC2=O ZDZDSZQYRBZPNN-UHFFFAOYSA-N 0.000 claims description 8
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 8
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000007958 sleep Effects 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 230000037322 slow-wave sleep Effects 0.000 claims description 6
- 208000009575 Angelman syndrome Diseases 0.000 claims description 5
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 102000014461 Ataxins Human genes 0.000 claims description 4
- 108010078286 Ataxins Proteins 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 4
- 206010044565 Tremor Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 230000002459 sustained effect Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004227 basal ganglia Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000037053 non-rapid eye movement Effects 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000037046 slow wave activity Effects 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 2
- 208000004552 Lacunar Stroke Diseases 0.000 claims description 2
- 208000002033 Myoclonus Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000003906 hydrocephalus Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 230000002688 persistence Effects 0.000 claims description 2
- 230000004620 sleep latency Effects 0.000 claims description 2
- 230000004622 sleep time Effects 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 3
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 claims 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 201000003415 fragile X-associated tremor/ataxia syndrome Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000012790 adhesive layer Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- -1 thimersol Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002630 speech therapy Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008939P | 2014-06-06 | 2014-06-06 | |
| US62/008,939 | 2014-06-06 | ||
| PCT/US2015/034018 WO2015187851A1 (en) | 2014-06-06 | 2015-06-03 | Methods of increasing tonic inhibition and treating secondary insomnia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019217208A Division JP2020063264A (ja) | 2014-06-06 | 2019-11-29 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516868A JP2017516868A (ja) | 2017-06-22 |
| JP2017516868A5 true JP2017516868A5 (enExample) | 2018-05-17 |
Family
ID=54767324
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516256A Withdrawn JP2017516868A (ja) | 2014-06-06 | 2015-06-03 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
| JP2019217208A Withdrawn JP2020063264A (ja) | 2014-06-06 | 2019-11-29 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
| JP2021116935A Withdrawn JP2021178836A (ja) | 2014-06-06 | 2021-07-15 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
| JP2023088456A Pending JP2023123442A (ja) | 2014-06-06 | 2023-05-30 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019217208A Withdrawn JP2020063264A (ja) | 2014-06-06 | 2019-11-29 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
| JP2021116935A Withdrawn JP2021178836A (ja) | 2014-06-06 | 2021-07-15 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
| JP2023088456A Pending JP2023123442A (ja) | 2014-06-06 | 2023-05-30 | 持続性抑制を増加させ、二次性不眠症を治療する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (11) | US20150352085A1 (enExample) |
| EP (3) | EP3795156A1 (enExample) |
| JP (4) | JP2017516868A (enExample) |
| AR (1) | AR100772A1 (enExample) |
| AU (4) | AU2015269667B2 (enExample) |
| CA (1) | CA2950845C (enExample) |
| CY (2) | CY1124366T1 (enExample) |
| DK (2) | DK3151832T3 (enExample) |
| ES (2) | ES2875742T3 (enExample) |
| HR (2) | HRP20210901T1 (enExample) |
| HU (2) | HUE055400T2 (enExample) |
| IL (2) | IL249287B (enExample) |
| LT (2) | LT3151832T (enExample) |
| MX (2) | MX391502B (enExample) |
| PL (2) | PL3151832T3 (enExample) |
| PT (2) | PT3151832T (enExample) |
| RS (2) | RS62007B1 (enExample) |
| SI (2) | SI3151832T1 (enExample) |
| SM (2) | SMT202100343T1 (enExample) |
| WO (1) | WO2015187851A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3065782B8 (en) | 2013-11-05 | 2021-05-26 | Elena Molokanova | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels |
| EP3795156A1 (en) | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Pharmaceutical composition for treating angelman syndrome |
| US10080898B2 (en) | 2015-05-29 | 2018-09-25 | Medtronic, Inc. | Simultaneous physiological sensing and stimulation with saturation detection |
| US10434308B2 (en) | 2015-05-29 | 2019-10-08 | Medtronic, Inc. | Impedance matching and electrode conditioning in patient interface systems |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| WO2018017639A1 (en) * | 2016-07-19 | 2018-01-25 | Georgia State University Research Foundation | Methods for treating rett syndrome |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
| US11181384B2 (en) * | 2018-07-23 | 2021-11-23 | Waymo Llc | Verifying map data using challenge questions |
| EP3833351A4 (en) * | 2018-09-20 | 2021-10-13 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS |
| KR20210110585A (ko) * | 2018-11-21 | 2021-09-08 | 썰테고 테라퓨틱스 아이엔씨. | 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌 |
| MX2021007224A (es) | 2018-12-17 | 2021-09-23 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas. |
| JP2022524927A (ja) | 2019-02-02 | 2022-05-11 | ステモニックス インコーポレイティド | 創薬のためのヒトスフェロイドの使用方法 |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| EP3982937A4 (en) * | 2019-07-15 | 2022-08-10 | Ovid Therapeutics Inc. | PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT |
| US11364228B2 (en) | 2019-12-18 | 2022-06-21 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| JP7600661B2 (ja) * | 2020-12-11 | 2024-12-17 | ａｒｔｉｅｎｃｅ株式会社 | 貼付剤 |
| AU2024220869A1 (en) | 2023-02-17 | 2025-09-04 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) * | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
| US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
| US20050137222A1 (en) * | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
| JP2007530604A (ja) | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
| DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| US20110046090A1 (en) * | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| JP5909750B2 (ja) | 2007-11-13 | 2016-04-27 | マリンクロット アイピー | 低用量静脈内アセトアミノフェン |
| CN102137667A (zh) * | 2008-09-01 | 2011-07-27 | H.隆德贝克有限公司 | 包含加波沙朵和patl或oat抑制剂的药物组合物 |
| EP3795156A1 (en) * | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Pharmaceutical composition for treating angelman syndrome |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2015
- 2015-06-03 EP EP20204995.3A patent/EP3795156A1/en active Pending
- 2015-06-03 RS RS20210718A patent/RS62007B1/sr unknown
- 2015-06-03 CA CA2950845A patent/CA2950845C/en active Active
- 2015-06-03 JP JP2017516256A patent/JP2017516868A/ja not_active Withdrawn
- 2015-06-03 RS RS20210711A patent/RS62006B1/sr unknown
- 2015-06-03 AU AU2015269667A patent/AU2015269667B2/en active Active
- 2015-06-03 EP EP15803364.7A patent/EP3151832B1/en active Active
- 2015-06-03 US US14/729,910 patent/US20150352085A1/en not_active Abandoned
- 2015-06-03 DK DK15803364.7T patent/DK3151832T3/da active
- 2015-06-03 SM SM20210343T patent/SMT202100343T1/it unknown
- 2015-06-03 HU HUE18169211A patent/HUE055400T2/hu unknown
- 2015-06-03 LT LTEP15803364.7T patent/LT3151832T/lt unknown
- 2015-06-03 SI SI201531616T patent/SI3151832T1/sl unknown
- 2015-06-03 HR HRP20210901TT patent/HRP20210901T1/hr unknown
- 2015-06-03 MX MX2020012404A patent/MX391502B/es unknown
- 2015-06-03 LT LTEP18169211.2T patent/LT3372229T/lt unknown
- 2015-06-03 PT PT158033647T patent/PT3151832T/pt unknown
- 2015-06-03 WO PCT/US2015/034018 patent/WO2015187851A1/en not_active Ceased
- 2015-06-03 MX MX2016016136A patent/MX380868B/es unknown
- 2015-06-03 PT PT181692112T patent/PT3372229T/pt unknown
- 2015-06-03 SI SI201531620T patent/SI3372229T1/sl unknown
- 2015-06-03 SM SM20210340T patent/SMT202100340T1/it unknown
- 2015-06-03 PL PL15803364T patent/PL3151832T3/pl unknown
- 2015-06-03 ES ES18169211T patent/ES2875742T3/es active Active
- 2015-06-03 HU HUE15803364A patent/HUE055155T2/hu unknown
- 2015-06-03 ES ES15803364T patent/ES2876350T3/es active Active
- 2015-06-03 DK DK18169211.2T patent/DK3372229T3/da active
- 2015-06-03 EP EP18169211.2A patent/EP3372229B1/en active Active
- 2015-06-03 PL PL18169211T patent/PL3372229T3/pl unknown
- 2015-06-05 AR ARP150101808A patent/AR100772A1/es not_active Application Discontinuation
- 2015-10-19 US US14/886,764 patent/US9339495B2/en active Active
-
2016
- 2016-04-19 US US15/132,641 patent/US9446028B2/en active Active
- 2016-11-04 US US15/343,690 patent/US9744159B2/en active Active
- 2016-11-29 IL IL249287A patent/IL249287B/en active IP Right Grant
- 2016-12-12 US US15/375,735 patent/US9801864B2/en active Active
-
2017
- 2017-06-09 US US15/618,736 patent/US20170273956A1/en not_active Abandoned
- 2017-09-27 US US15/716,726 patent/US20180015076A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/023,282 patent/US11278529B2/en active Active
-
2019
- 2019-08-27 IL IL268960A patent/IL268960B/en active IP Right Grant
- 2019-11-29 JP JP2019217208A patent/JP2020063264A/ja not_active Withdrawn
-
2020
- 2020-08-11 AU AU2020217342A patent/AU2020217342B2/en active Active
-
2021
- 2021-06-07 HR HRP20210902TT patent/HRP20210902T1/hr unknown
- 2021-06-10 CY CY20211100509T patent/CY1124366T1/el unknown
- 2021-06-10 CY CY20211100510T patent/CY1124368T1/el unknown
- 2021-07-15 JP JP2021116935A patent/JP2021178836A/ja not_active Withdrawn
- 2021-09-30 US US17/490,650 patent/US20220016091A1/en not_active Abandoned
-
2022
- 2022-01-07 AU AU2022200085A patent/AU2022200085A1/en not_active Abandoned
- 2022-08-08 US US17/882,939 patent/US20230051859A1/en not_active Abandoned
-
2023
- 2023-05-30 JP JP2023088456A patent/JP2023123442A/ja active Pending
-
2024
- 2024-04-22 AU AU2024202604A patent/AU2024202604A1/en active Pending
- 2024-10-03 US US18/905,678 patent/US20250025448A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020217342B2 (en) | Methods of increasing tonic inhibition and treating secondary insomnia | |
| US20080089861A1 (en) | Combination therapy for treatment of demyelinating conditions | |
| KR20150003765A (ko) | 라퀴니모드와 디메틸 푸마레이트의 병용물에 의한 다발성 경화증의 치료 | |
| CN110300581B (zh) | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 | |
| WO2015171547A1 (en) | Methods of treating cognitive impairment associated with neurodegenerative disorders | |
| HUE030963T2 (en) | Sustained release formulations containing a 2-oxo-pyrrolidine derivative | |
| WO2017189504A1 (en) | Highly selective adenosine a3 receptor subtype agonsists for the prevention and treatment of neurodegenerative disorders | |
| JP2503571B2 (ja) | 脳循環代謝改善剤 | |
| US11826341B2 (en) | Baicalein analogs for use in neuroprotection and regulation of immune reactivity | |
| CN112043700A (zh) | 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用 | |
| JP2020186254A (ja) | 自閉症の治療 | |
| CN103070850B (zh) | 具有良好体内行为的口服固体药物组合物 | |
| WO2024254701A1 (en) | Ibogaine for the treatment of multiple sclerosis | |
| CN117338938A (zh) | 用于治疗中枢神经系统紊乱的组合疗法 | |
| WO2019041778A1 (zh) | 麝香酮在制备治疗神经免疫性疾病药物中的应用 | |
| US20120202746A1 (en) | Daptomycin for multiple sclerosis | |
| IT202300009258A1 (it) | Nuova associazione di principi attivi, composizioni farmaceutiche e/o nutraceutiche che la contengono e loro uso nella prevenzione e riparazione dei danni del sistema nervoso centrale e periferico | |
| JP2008524174A (ja) | ジヒドロイミダゾピラジン誘導体の疼痛治療又は予防のための利用 | |
| RU2393861C1 (ru) | Композиция для лечения рассеянного склероза (варианты) | |
| HUE027934T2 (en) | Combination for the prevention and treatment of behavioral, mental and cognitive disorders | |
| Vgenopoulou et al. | Melatonin levels in Alzheimer disease | |
| JP2021512857A (ja) | Ｎｍｄａ受容体アゴニストの投与方法 | |
| HK40021759B (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| JP2015508417A (ja) | 神経変性障害を治療するためのジアジリジン | |
| JP2015509104A (ja) | 神経変性障害を治療するためのジアジリジン |